Overview

Randomized Pilot Trial of Antimicrobial Therapy and Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To determine if the addition of vancomycin to SBRT increases a Th1 immune response measured by cytokine expression (IFN gamma)
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania
Treatments:
Anti-Bacterial Agents
Anti-Infective Agents
Vancomycin